Alnylam Pharmaceuticals, Inc. (ALNY)
291.42
-11.63
(-3.84%)
USD |
NASDAQ |
Jun 08, 14:30
Alnylam Pharmaceuticals EPS Diluted (Quarterly) : 1.508 for March 31, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Ionis Pharmaceuticals, Inc. | -0.5612 |
| Incyte Corp. | 1.467 |
| BioMarin Pharmaceutical, Inc. | 0.5431 |
| BridgeBio Pharma, Inc. | -0.8422 |
| Insmed, Inc. | -0.7591 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 205.99M |
| Revenue (Quarterly) | 1.167B |
| Total Expenses (Quarterly) | 961.18M |
| Enterprise Value | 40.40B |
| Gross Profit Margin (Quarterly) | 81.91% |
| Profit Margin (Quarterly) | 17.65% |
| Earnings Yield | 1.44% |
| Operating Earnings Yield | 1.90% |
| Normalized Earnings Yield | 1.415 |